CLINICAL TRIALS PROFILE FOR BRUKINSA

All Clinical Trials for BRUKINSA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03145064 ↗	Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma	Completed	BeiGene	Phase 2	2017-06-30	Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow-up, or study termination from sponsor; treatment (up to 2 years), safety follow-up (30 days); survival follow-up until data cutoff for final analysis.
NCT03332017 ↗	A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma	Active, not recruiting	BeiGene	Phase 2	2017-11-15	The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma.
NCT03336333 ↗	A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL	Recruiting	BeiGene	Phase 3	2017-11-02	To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival.
NCT04002297 ↗	Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma	Recruiting	BeiGene	Phase 3	2019-08-21	This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
NCT04116437 ↗	Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment	Recruiting	BeiGene	Phase 2	2019-10-15	The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma patients who have become intolerant of prior ibrutinib and/or acalabrutinib treatment, by comparing intolerance to adverse event profile as assessed by the recurrence and the change in severity of adverse events.

Clinical Trial Conditions for BRUKINSA

Condition Name

Condition Name for BRUKINSA
Intervention	Trials
Small Lymphocytic Lymphoma	3
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	2
Refractory Transformed B-Cell Non-Hodgkin Lymphoma	2
Diffuse Large B-cell Lymphoma	2

Condition MeSH

Condition MeSH for BRUKINSA
Intervention	Trials
Lymphoma	17
Lymphoma, B-Cell	7
Leukemia, Lymphoid	7
Leukemia, Lymphocytic, Chronic, B-Cell	7

Clinical Trial Locations for BRUKINSA

Trials by Country

Trials by Country for BRUKINSA
Location	Trials
United States	92
China	28
Australia	22
France	14
Japan	11

Trials by US State

Trials by US State for BRUKINSA
Location	Trials
Texas	7
Florida	6
Illinois	6
New York	5
Nevada	5

Clinical Trial Progress for BRUKINSA

Clinical Trial Phase

Clinical Trial Phase for BRUKINSA
Clinical Trial Phase	Trials
PHASE2	1
Phase 3	5
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for BRUKINSA
Clinical Trial Phase	Trials
Not yet recruiting	12
RECRUITING	11
Completed	3

Clinical Trial Sponsors for BRUKINSA

Sponsor Name

Sponsor Name for BRUKINSA
Sponsor	Trials
BeiGene	17
National Cancer Institute (NCI)	4
Peking Union Medical College Hospital	2

Sponsor Type

Sponsor Type for BRUKINSA
Sponsor	Trials
Industry	21
Other	15
NIH	4

BRUKINSA (Zanubrutinib): Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the Current Status of BRUKINSA Clinical Trials?

BRUKINSA (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene for hematologic malignancies. Since its FDA approval in November 2019 for mantle cell lymphoma (MCL), the drug has undergone multiple clinical trials across various blood cancers.

Key Clinical Trials

Trial Name	Phase	Indication	Enrollment	Outcome Highlights	Status
BGB-3111-2101	Phase III	Waldenström's Macroglobulinemia (WM)	128	Non-inferior to ibrutinib, with fewer atrial fibrillation cases	Ongoing
ALPINE (NCT03734016)	Phase III	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	580	Superior to ibrutinib in progression-free survival (PFS); fewer adverse events	Completed
Wizard	Phase III	Relapsed/Refractory MCL	86	Superior response rate, fewer severe adverse events	Completed
AUGMENT (NCT03112174)	Phase III	Waldenström's Macroglobulinemia	150	Demonstrated durable responses; safety profile consistent	Ongoing

Regulatory Progress

• Approved in the U.S. for MCL (2019) via accelerated approval based on objective response rate.
• Approved in China (2022), with ongoing applications elsewhere.
• Fast-track designations granted for WM and CLL in the U.S.

Market Analysis for BRUKINSA

Market Size and Growth Drivers

The global hematologic malignancies market was valued at USD 9.5 billion in 2022 and is projected to reach USD 14.2 billion by 2030, at a CAGR of 5.2% [1].

Key growth drivers include:

• Rising incidence of MCL, CLL, and WM
• Shift toward oral targeted therapies
• Increasing adoption of BTK inhibitors

Competitive Landscape

Major competitors:

Drug	Company	Indication	Market Share (2022)	US Launch Year
BRUKINSA	BeiGene	MCL, WM, CLL	22%	2019
Imbruvica (ibrutinib)	Pharmacyclics/Janssen	Multiple	50%	2013
Venclexta (venetoclax)	AbbVie	CLL, AML	14%	2016

BRUKINSA accounts for a growing segment, especially among patients with cardiac comorbidities, due to its lower atrial fibrillation incidence compared to ibrutinib.

Pricing and Reimbursement

In the U.S., the average wholesale price (AWP) is approximately USD 16,776 per 30-day supply [2]. Insurance coverage and reimbursement policies influence market penetration in different regions.

Market Projection and Future Opportunities

Sales Forecast (2023–2030)

Year	Estimated Global Sales (USD Billion)	Source
2023	1.2	Analyst estimates
2025	2.4	Market research reports
2030	3.5	Targeted market penetration

Growth is driven by expanded indications, including first-line therapy for CLL/SLL, and potential approvals for additional hematologic cancers such as Waldenström's macroglobulinemia and marginal zone lymphoma.

Pipeline and Development Opportunities

• Trials underway for combination regimens with venetoclax and anti-CD20 therapies.
• Exploring use in solid tumors with BTK expression.
• Potential in autoimmune diseases due to BTK's role in B-cell activation.

Regulatory and Patent Outlook

• Continued regulatory submissions anticipated in Europe and Asia.
• Patent protections extend until approximately 2030; potential generics may influence pricing.

Key Takeaways

BRUKINSA demonstrates promising clinical efficacy and a favorable safety profile in multiple hematologic malignancies, supported by robust trial data. Market growth is concentrated on its differentiated profile from competitors, especially in patient subsets with cardiac risks. Sales are expected to increase with expanded indications and geographic expansion.

FAQs

1. How does BRUKINSA differ from ibrutinib?
BRUKINSA has fewer off-target effects, leading to a lower incidence of adverse events like atrial fibrillation, making it suitable for patients with cardiovascular comorbidities.

2. What are the main indications for BRUKINSA?
It is approved for mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia.

3. What are the primary trial results supporting BRUKINSA’s efficacy?
Clinical trials demonstrate non-inferiority or superiority to existing therapies like ibrutinib, with durable responses and fewer severe adverse events.

4. What market factors influence BRUKINSA’s adoption?
Pricing, reimbursement policies, physician preference for oral targeted therapies, and competitive landscape all impact its market penetration.

5. What are the future development prospects for BRUKINSA?
Expanded indications, new combination therapies, and potentially broader applications in autoimmune diseases are under investigation.

---

References:

[1] Market Research Future. (2023). Hematologic Malignancies Market Analysis.
[2] Medicare.gov. (2023). Part D Prescription Drug Pricing Data.